Neuroscience biotech company Cerecor has acquired exclusive, worldwide rights to develop and commercialize MK-0657 from Merck, referred to MSD outside the US and Canada. The small molecule NMDA receptor subunit 2B antagonist MK-0657 will ...
Tags: Cerecor, Global Development Rights, MK-0657